Oral News and Research

RSS

Autism Speaks releases two new ATN tool kits

Autism Speaks, North America's leading autism science and advocacy organization, today released the Sleep Strategies for Children with Autism: A Parent's Guide and Treating Children with Autism Spectrum Disorders: A Tool Kit for Dental Professionals, both available for free download on Autism Speaks Tools You Can Use webpage.

22 Feb 2012

GTx fourth quarter net loss increases to $10.7 million

GTx, Inc. today provided a Company update and reported financial results for the fourth quarter and full year 2011.

21 Feb 2012

S1 submits Lorexys IND application for HSDD and Female Sexual Dysfunction treatment

S1 Pharmaceuticals, Inc. (S1) announced today that it has submitted its Investigational New Drug (IND) application to the U.S. Food and Drug Administration for Phase I-b clinical studies of SIP-104 (Lorexys). Lorexys is the Company's lead drug candidate for the treatment of Hypoactive Sexual Desire Disorder (HSDD) and Female Sexual Dysfunction (FSD).

21 Feb 2012

Substituting smokeless tobacco products can save smokers' lives

Substituting smokeless tobacco products can save smokers' lives, and there is a scientific foundation that proves it.

20 Feb 2012

NPAF commends passage of bill for parity in insurance coverage for orally administered chemotherapy

Representatives of Virginia's patient advocacy community praised the State House of Representatives and State Senate today for voting strongly in support of legislation that, if enacted, will help thousands of Virginia's insured cancer patients who are currently unable to access their physician-prescribed chemotherapy treatment regimens of choice.

18 Feb 2012

Aptuit sells Clinical Trials Supply business to Catalent Pharma Solutions

Aptuit announces the completion of the sale of the Clinical Trials Supply business to Catalent Pharma Solutions on February 17, 2012. Timothy C. Tyson, Chairman and CEO of Aptuit, LLC stated that Aptuit will continue to deliver scientific and service excellence to provide integrated capabilities for the early to mid phase drug development markets.

18 Feb 2012

Scientists discover the off signal for inflammation

Proteins, the building block for all living organisms, are the ultimate transformers - able to splice and switch roles and functions within the human body. But when these changes go wrong, diseases such as cancers and arthritis may result, says University of British Columbia researcher Chris Overall.

18 Feb 2012

Par Pharmaceutical acquires Edict

Par Pharmaceutical Companies, Inc. announced today that it has completed the acquisition of privately-held Edict Pharmaceuticals Private Limited, an India-based developer and manufacturer of generic pharmaceuticals.

18 Feb 2012

People experience eating problems and risk of malnutrition three months after stroke

People who suffered a stroke continued to experience eating problems and more than half still risked malnutrition after three months, even though there had been a marked improvement in most of their physical functions.

17 Feb 2012

Indian authorities vaccinate children crossing India-Pakistan border; Distrust of polio vaccines grows in Pakistan

After going a year without recording a polio case, Indian health officials have begun vaccinating young children who cross the border to or from Pakistan at the Munabao railway station in Rajasthan state, BBC News reports.

17 Feb 2012

BioCryst fourth quarter revenues decrease to $5.2 million

BioCryst Pharmaceuticals, Inc. announced financial results for the fourth quarter and full year ended December 31, 2011.

16 Feb 2012

Study identifies variations in non-pharmacological palliative care

Faced with the inevitability of death, we all wish for good caregiving during the final stage of our lives. A new study from Karolinska Institutet and Ume- University shows that non-pharmacological caregiving at the end of life in specialized palliative care is not as basic as one might believe but is based on complex professional decisions that weave physical, psychosocial and existential dimensions into a functional whole.

16 Feb 2012

Smoking kills healthy bacteria and leads to infection

According to a new study, smoking causes the body to turn against its own helpful bacteria, leaving smokers more vulnerable to disease.

16 Feb 2012

U.S. FDA accepts Pfizer's tafamidis NDA for treatment of TTR-FAP

Pfizer Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for tafamidis meglumine, the company's investigational, novel, oral therapy for the treatment of Transthyretin Familial Amyloid Polyneuropathy.

16 Feb 2012

Study to examine relationship between oral and silent reading in children

When a beginning reader reads aloud, her progress is apparent: Hunched over a book, little index finger blazing the way, she moves intently from sound to sound, word to word. I do not like green eggs and ham! I do not like them, Sam-I-am! But when that same child reads silently, it's much harder to measure how much she is reading -- or understanding. Yet as she advances through school, teachers will expect her to learn increasingly through silent rather than oral reading.

15 Feb 2012

Paricalcitol does not improve clinical outcomes for patients with CKD

Patients with chronic kidney disease who received the vitamin D compound paricalcitol for up to 48 weeks did not show improvement on measures of cardiac structure, function, or left ventricular mass, compared to patients who received placebo, according to a study in the February 15 issue of JAMA.

15 Feb 2012

Mich. Attorney General to sue administration on birth control rule

While officials at some hospitals and universities expressed support for Obama administration's compromise last week, other religious and governmental leaders remained unsatisfied, according to media reports.

14 Feb 2012

Oral blood samples from patients with periodontal disease can measure hemoglobin A1c

Oral blood samples drawn from deep pockets of periodontal inflammation can be used to measure hemoglobin A1c, an important gauge of a patient's diabetes status, an NYU nursing-dental research team has found.

14 Feb 2012

Tiltan initiates TL-118 Phase 2 clinical trial for pancreatic cancer

Tiltan Pharma Ltd. today announced that it has commenced a Phase 2 clinical trial of its anti-angiogenic product TL-118 for the treatment of pancreatic cancer.

13 Feb 2012

Santarus initiates enrollment in UCERIS Phase IIIb study for ulcerative colitis

Santarus, Inc. today announced that it has begun patient enrollment in a multicenter, randomized, double-blind, placebo-controlled Phase IIIb clinical study with the investigational drug UCERIS (budesonide) tablets 9 mg to evaluate whether there is an incremental benefit when UCERIS 9 mg is added to current oral aminosalicylate (5-ASA) therapy for patients with mild or moderate active ulcerative colitis who are not adequately controlled on background 5-ASA therapy.

13 Feb 2012